Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Choreatic Disorder Clear all
Completed No phase listed Observational

Memory Disorders Registry

NCT00654563
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Parkinson Disease, Huntington Disease
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019
View directory record Official record
Conditions
Huntington Disease, Irritability
Interventions
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

NCT04102579
View directory record Official record
Conditions
Chorea, Huntington
Interventions
Valbenazine, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 15, 2026, 4:53 PM EDT
Completed No phase listed Observational

HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States

NCT03628235
View directory record Official record
Conditions
Huntington's Disease
Interventions
Online survey
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Englewood, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Effects of Music Therapy on Huntington's Disease

NCT00178360
View directory record Official record
Conditions
Huntington's Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 15, 2026, 4:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

NCT03225846
View directory record Official record
Conditions
Huntington's Disease
Interventions
WVE-120102, Placebo
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

NCT04556656
View directory record Official record
Conditions
Huntington Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
25 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Davis, California • San Diego, California • Englewood, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 15, 2026, 4:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT02855476
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
University College, London
Other
Eligibility
11 Years to 75 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2017
U.S. locations
6
States / cities
Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 15, 2026, 4:53 PM EDT
Terminated Phase 3 Interventional

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

NCT00712426
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine Monohydrate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
38
States / cities
Birmingham, Alabama • Irvine, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 15, 2026, 4:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

NCT06273150
View directory record Official record
Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
Positive genetic test for pathological expansion in ATN1
Other
Lead sponsor
University College, London
Other
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

NCT01485965
View directory record Official record
Conditions
Huntington's Disease
Interventions
SEN0014196
Drug
Lead sponsor
Siena Biotech S.p.A.
Industry
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2007 · Synced Sep 15, 2026, 4:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complex Eye Movements in Parkinson's Disease and Related Movement Disorders

NCT04925622
View directory record Official record
Conditions
Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonian Disorders, Essential Tremor, Vascular Parkinsonism, Multiple System Atrophy, Parkinson Variant, Parkinsonian Syndrome, Huntington Disease
Interventions
Complex eye movement exam
Diagnostic Test
Lead sponsor
Saccadous, Inc.
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 15, 2026, 4:53 PM EDT
Not listed Phase 4 Interventional

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

NCT02509793
View directory record Official record
Conditions
Huntington's Disease
Interventions
Tetrabenazine
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Not applicable Interventional

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

NCT03417583
View directory record Official record
Conditions
Huntington Disease
Interventions
Protocol Intervention Group
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

NCT00212316
View directory record Official record
Conditions
Huntington's Disease
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Sep 15, 2026, 4:53 PM EDT
Completed No phase listed Observational Results available

Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease

NCT01451463
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

NCT00788047
View directory record Official record
Conditions
Huntington Disease, Alzheimer Disease
Interventions
Dextromethorphan, Dimebon + Dextromethorphan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Sep 15, 2026, 4:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

University of Central Florida CereBank

NCT06876857
View directory record Official record
Conditions
Biospecimen Donation, Brain Injury, Brain Diseases
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2075
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 15, 2026, 4:53 PM EDT
Completed No phase listed Observational

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06667414
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 60 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

NCT03515213
View directory record Official record
Conditions
Huntington Disease
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 15, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Alternatives for Reducing Chorea in Huntington Disease

NCT01897896
View directory record Official record
Conditions
Chorea Associated With Huntington Disease
Interventions
SD-809
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 15, 2026, 4:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders

NCT00056888
View directory record Official record
Conditions
Movement Disorders
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 15, 2026, 4:53 PM EDT